<html>
<body bgcolor="#99FF66" >
<table align="center" border="1" style="width: 90%; height: 80%;">
<tbody>
<tr>
<td height="420" valign="top" bgcolor="#CCCCCC" style="padding-top:
10px;">
<table align="center" border="1" style="width: 98%;">
<tbody>
<tr bgcolor="#99FF99">
<td height="77">
<p align="left " style="font-family: 'Georgia',Helvetica; padding: 12px 0px
7px 0px; margin: 0px; color: #765e31; font-size: 24px; font-weight: bold;
letter-spacing: -1px; display: block; border-bottom: dashed 1px
#ccc;"><b>Nuvilex, Inc.</b><span> (NVLX)</span></p>
<p align="center" color:="" 765e31="" 8b661f="" 9b6a0d=""
b47908=""><strong><em><strong><b><b><strong><b>Nuvilex, Inc. to Run 2 of
the 3 Large Med Markets with Cell Encapsulation
Technology</b></strong></b></b></strong></em></strong></p>
</td>
</tr>
<tr bgcolor="#d3ecd0">
<td height="202">
<p><span>Behind forming a block-buster deal to procure Bio Blue Bird and
its world-wide licenses connected to the live-cell encapsulation platform
technology to advance therapies for all can_cer types, <b>Nuvilex,
Inc.</b> (OTCQB: <b>NVLX</b>) broadcast this week that it now
anticipates to do the same thing with dia-betes. </span></p>
<p><span>When Nuvilex finalizes this procurement, it <b>will be in
control of 2 of the big 3 multi-bil_lion dol_lar dr_ug
markets</b> – can_cer and diabe-tes – with respect to the
use of this unique and exclusive live-cell encapsulation
technology. </span></p>
<p><span>The company’s objective is to secure the exclusive global
rights for the use of the live-cell encapsulation technology for the
development of therapies for Dia.be.tes from SG Austria P.t.e.
Ltd. Per the American Dia-betes Association, <b>in the USA
al0ne, $176 bil-lion is spent annually on medical expe-nditures associated
with dia-betes</b> with over $22 bil-lion of that being paid on
therapies for the dis-ease. Nuvilex said it anticipates to close this
deal at the close of October.</span><br /><br /><span>5847 San Felipe, 17th
FL, Houston, TX 77057 U.S.A.</span></p>
<p> </p>
</td>
</tr>
</tbody>
</table>
<table align="center" border="1" style="width: 98%;">
<tbody>
<tr>
<td bgcolor="#90a78e">
<p align="center" style="font-family: 'Verdana'; font-size: 9px; color:
#7b7575; text-align: center;"><span style="font-family: arial, helvetica,
sans-serif; font-size: x-small;">The use of research materials circulated
by the auth.or is done at your own risk. You are encouraged to do your own
research before making any investment decision in regards to the secu rity
discussed herein. The author has been give 5k in connection with the
distribution of these materials. You should presume that as of the date of
this report or letter, the author, possibly along with or through our
owners, affiliates, employees and/or consultants, (cooperatively referred
to as the author) has a position in all company shares (and/or options of
the shares) covered herein that is consistent with the position set forth
in our report. In connection with NVLX, the author has taken a long
position. Following the disbursement of any report or letter, the author
intends to continue engaging in trnsactns in the secu rity covered herein,
and we may be long, short, and/or neutral at any time hereafter regardless
of our initial position and we preserve the right to procure or trade all
or part of our position at any time without notice. This practice could end
in our trading securities at any time before, during, and/or after the
disbursement of this report.<br /> <br /> <a
href="http://srvr.mulatearequerrymu.net/unsubscribe.php?M=6588707&C=0a89a74737fe0ab850bde605efc11be4&L=54&N=2751"><span>Discontinue
Communications</span></a></span></p>
</td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr></tr>
</tbody>
</table>
<img
src="http://srvr.mulatearequerrymu.net/open.php?M=6588707&L=54&N=2751&F=H&image=.jpg"
height="1" width="10"></body>